Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee under Nasdaq Listing Rule 5635(c)(4). The option covers 8,400 shares at an exercise price of $1.02 per share, vests over four years, and has a 10-year term.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
On the day this news was published, AKBA declined 8.20%, reflecting a notable negative market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $23M from the company's valuation, bringing the market cap to $255.38M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Conference presentation | Neutral | +1.9% | Announced management presentation at 2026 Jefferies Global Healthcare Conference. |
| May 07 | Earnings report | Negative | -20.3% | Q1 2026 revenues declined and net loss of $9.1M reported. |
| May 04 | Inducement grants | Neutral | -3.3% | Granted options for 208,800 shares to seven new hires under Rule 5635(c)(4). |
| May 04 | Clinical data | Positive | +7.1% | Published Phase 3 vadadustat analysis showing statistically significant mortality/hospitalization benefit. |
| Apr 30 | Earnings timing | Neutral | +1.4% | Announced date and call details for Q1 2026 financial results release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Fundamental updates and data (earnings, clinical publication) previously drove clearer reactions, while corporate/administrative items like conferences or inducement grants saw relatively modest moves.
Over recent months, Akebia reported Q1 2026 results with $53.5M in total revenues and a $9.1M net loss, which preceded a double‑digit price decline. By contrast, publication of statistically significant vadadustat Phase 3 analysis news coincided with a strong gain. Conference participation and prior inducement grants produced smaller, mixed reactions. Today’s single‑employee inducement grant fits into this pattern of routine corporate items, against a backdrop of ongoing commercial execution and kidney‑disease pipeline work.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
